Oncology

The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs. 
[[thumbnail_alt_text]]
Dawn Hershman, MD, MS, offers some potential treatments for aromatase inhibitor-caused arthralgia in breast cancer patients. This video was filmed at the 2019 San Antonio Breast Cancer Symposium.
[[thumbnail_alt_text]]
A discussion of the PAOLO-1 trial regimen and the rationale behind combining olaparib and bevacizumab as post-chemotherapy maintenance.
[[thumbnail_alt_text]]
Belantamab mafodotin has the potential for durable responses in patients with multiple myeloma whose disease has relapsed or is resistant to standard therapies.
[[thumbnail_alt_text]]
Because of the vulnerabilities of CDK4/6i-resistant tumors, researchers believe that it is imperative to improve the survival of this group of patients.
[[thumbnail_alt_text]]
The rise in value-based reimbursement models has required oncology care providers to assume an unprecedented level of accountability.
[[thumbnail_alt_text]]
The decline in the cancer mortality rate attributed to immunotherapy methods, early detection, and treatment.
[[thumbnail_alt_text]]
Maurie Markman, MD, leads a discussion on the design and results of the PRIMA trial, and how it has impacted practice.
[[thumbnail_alt_text]]
After injecting the flu vaccine into a tumor cell, researchers found that the injection either slowed the growth or shrunk the tumor itself.
[[thumbnail_alt_text]]
Key opinion leaders discuss the importance of HRD testing, with special consideration of tissue testing versus somatic testing.
[[thumbnail_alt_text]]
This medication is the first precision therapy approved to treat a genomically defined population of patients with GIST, according to Blueprint Medicines.